By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BIND Therapeutics 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-491-3400 Fax: 617-491-0351


Company News
BIND Therapeutics (BIND) To Report First Quarter 2016 Financial Results On May 9, 2016 5/4/2016 11:14:27 AM
Cambridge's BIND Therapeutics (BIND) Files for Chapter 11 and Reviews Strategic Alternatives 5/2/2016 6:01:58 AM
Peptidream Announces Research Collaboration With BIND Therapeutics (BIND) 4/6/2016 10:17:10 AM
Shift in R&D Strategy Forces BIND Therapeutics (BIND) to Slash 38% of Workforce, Look for New Capital and Deals 4/6/2016 8:02:44 AM
BIND Therapeutics (BIND) Reports Fourth Quarter And Full Year 2015 Financial Results And Announces Shift In Research And Discovery Strategy To Focus On Based On ACCURINS® Platform Developing Innovative Medicines 3/15/2016 12:52:22 PM
BIND Therapeutics (BIND) To Report Fourth Quarter And Year-End 2015 Financial Results On March 15, 2016 3/9/2016 11:05:45 AM
BIND Therapeutics (BIND) And Synergy Pharma Announce Collaboration To Develop ACCURINS® With Proprietary Uroguanylin Analogs For Targeting Gastrointestinal Receptors On Tumors 2/16/2016 11:06:15 AM
BIND Therapeutics (BIND) Release: AZD2811 ACCURINS Data Published In Science Translational Medicine Highlight One Of The First Applications Of Nanomedicine To Molecularly Targeted Cancer Therapies 2/11/2016 9:43:38 AM
BIND Therapeutics (BIND) Provides Enrollment Update For Phase II Insite 1 And Insite 2 Trials With BIND-014 1/27/2016 8:50:20 AM
BIND Therapeutics (BIND) Complete Data On Clinical Activity Of BIND-014 In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc) At The 2016 Genitourinary Cancers Symposium 1/7/2016 11:07:51 AM